Oncolytics gets broader patent coverage for reovirus

By E. Janene Geiss

Philadelphia, Oct. 20 - Oncolytics Biotech Inc. announced Thursday that it received a Canadian patent for reovirus to treat not only Ras-mediated neoplasia, but also for use in various cancers.

Canadian Patent 2,283,280 entitled, "Reovirus for the treatment of neoplasia," describes the use of the reovirus in making a medicine that treats neoplasia, along with describing methods of treating various cancers by administering reovirus, according to a company news release.

"The claims in Oncolytics' third Canadian patent provide additional coverage for the use of the reovirus in treating cancers," said Matt Coffey, chief scientific officer for Oncolytics.

Oncolytics is a Calgary, Alta.-based biotechnology company focused on the development of Reolysin, a proprietary formulation of the human reovirus as a cancer therapeutic.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.